Cargando…

Premature phase II study of amrubicin as palliative chemotherapy for previously treated malignant pleural mesothelioma

BACKGROUND: Treatment options for malignant pleural mesothelioma (MPM) are limited. Anthracyclines are considered key drugs for treating MPM. However, their use is limited by severe cardiac toxicities. Amrubicin (AMR) is a next‐generation anthracycline that is commonly used to treat lung cancer. Her...

Descripción completa

Detalles Bibliográficos
Autores principales: Watanabe, Kageaki, Okuma, Yusuke, Kawai, Shoko, Nagamata, Makoto, Hosomi, Yukio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8169308/
https://www.ncbi.nlm.nih.gov/pubmed/33830645
http://dx.doi.org/10.1111/1759-7714.13892
_version_ 1783702032152002560
author Watanabe, Kageaki
Okuma, Yusuke
Kawai, Shoko
Nagamata, Makoto
Hosomi, Yukio
author_facet Watanabe, Kageaki
Okuma, Yusuke
Kawai, Shoko
Nagamata, Makoto
Hosomi, Yukio
author_sort Watanabe, Kageaki
collection PubMed
description BACKGROUND: Treatment options for malignant pleural mesothelioma (MPM) are limited. Anthracyclines are considered key drugs for treating MPM. However, their use is limited by severe cardiac toxicities. Amrubicin (AMR) is a next‐generation anthracycline that is commonly used to treat lung cancer. Here, we conducted a phase II trial of this drug in patients with previously treated MPM. METHODS: Eligible patients with MPM having adequate organ function and a performance status of 0–2 were enrolled after disease progression following pemetrexed/platinum therapy. Patients received 35 mg/m(2) AMR on days 1–3 every three weeks until tumor progression or the appearance of unacceptable toxicities. The primary endpoint was the objective response rate. Median progression‐free survival (PFS), overall survival (OS), number of treatment cycles, and adverse events were evaluated as secondary endpoints. RESULTS: This trial was discontinued because of low accrual. From September 2013 to July 2018, five patients with MPM were enrolled. Stable disease (SD) was observed in three patients (60%), and progressive disease was noted in two patients (40%). The median PFS was 2.4 (range, 1.2–11.2) months, and the median OS was 9.1 (range, 6.2–22.0) months. The median number of treatment cycles was three (range, 2–11). Grade 1/2 toxicities were observed in all patients. Grade 3/4 neutropenia was observed in four patients (80%), but there were no cases of febrile neutropenia. CONCLUSIONS: Despite the absence of the responders, the observation of SD in three patients suggests that AMR could have potential for treating MPM.
format Online
Article
Text
id pubmed-8169308
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley & Sons Australia, Ltd
record_format MEDLINE/PubMed
spelling pubmed-81693082021-06-05 Premature phase II study of amrubicin as palliative chemotherapy for previously treated malignant pleural mesothelioma Watanabe, Kageaki Okuma, Yusuke Kawai, Shoko Nagamata, Makoto Hosomi, Yukio Thorac Cancer Original Articles BACKGROUND: Treatment options for malignant pleural mesothelioma (MPM) are limited. Anthracyclines are considered key drugs for treating MPM. However, their use is limited by severe cardiac toxicities. Amrubicin (AMR) is a next‐generation anthracycline that is commonly used to treat lung cancer. Here, we conducted a phase II trial of this drug in patients with previously treated MPM. METHODS: Eligible patients with MPM having adequate organ function and a performance status of 0–2 were enrolled after disease progression following pemetrexed/platinum therapy. Patients received 35 mg/m(2) AMR on days 1–3 every three weeks until tumor progression or the appearance of unacceptable toxicities. The primary endpoint was the objective response rate. Median progression‐free survival (PFS), overall survival (OS), number of treatment cycles, and adverse events were evaluated as secondary endpoints. RESULTS: This trial was discontinued because of low accrual. From September 2013 to July 2018, five patients with MPM were enrolled. Stable disease (SD) was observed in three patients (60%), and progressive disease was noted in two patients (40%). The median PFS was 2.4 (range, 1.2–11.2) months, and the median OS was 9.1 (range, 6.2–22.0) months. The median number of treatment cycles was three (range, 2–11). Grade 1/2 toxicities were observed in all patients. Grade 3/4 neutropenia was observed in four patients (80%), but there were no cases of febrile neutropenia. CONCLUSIONS: Despite the absence of the responders, the observation of SD in three patients suggests that AMR could have potential for treating MPM. John Wiley & Sons Australia, Ltd 2021-04-08 2021-06 /pmc/articles/PMC8169308/ /pubmed/33830645 http://dx.doi.org/10.1111/1759-7714.13892 Text en © 2021 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Watanabe, Kageaki
Okuma, Yusuke
Kawai, Shoko
Nagamata, Makoto
Hosomi, Yukio
Premature phase II study of amrubicin as palliative chemotherapy for previously treated malignant pleural mesothelioma
title Premature phase II study of amrubicin as palliative chemotherapy for previously treated malignant pleural mesothelioma
title_full Premature phase II study of amrubicin as palliative chemotherapy for previously treated malignant pleural mesothelioma
title_fullStr Premature phase II study of amrubicin as palliative chemotherapy for previously treated malignant pleural mesothelioma
title_full_unstemmed Premature phase II study of amrubicin as palliative chemotherapy for previously treated malignant pleural mesothelioma
title_short Premature phase II study of amrubicin as palliative chemotherapy for previously treated malignant pleural mesothelioma
title_sort premature phase ii study of amrubicin as palliative chemotherapy for previously treated malignant pleural mesothelioma
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8169308/
https://www.ncbi.nlm.nih.gov/pubmed/33830645
http://dx.doi.org/10.1111/1759-7714.13892
work_keys_str_mv AT watanabekageaki prematurephaseiistudyofamrubicinaspalliativechemotherapyforpreviouslytreatedmalignantpleuralmesothelioma
AT okumayusuke prematurephaseiistudyofamrubicinaspalliativechemotherapyforpreviouslytreatedmalignantpleuralmesothelioma
AT kawaishoko prematurephaseiistudyofamrubicinaspalliativechemotherapyforpreviouslytreatedmalignantpleuralmesothelioma
AT nagamatamakoto prematurephaseiistudyofamrubicinaspalliativechemotherapyforpreviouslytreatedmalignantpleuralmesothelioma
AT hosomiyukio prematurephaseiistudyofamrubicinaspalliativechemotherapyforpreviouslytreatedmalignantpleuralmesothelioma